Gilead wins ap­proval for long-act­ing HIV in­jec­tion af­ter re­solv­ing vial con­cerns

Gilead fi­nal­ly gained FDA ap­proval on Thurs­day for lenaca­pavir, its close­ly-watched cap­sid in­hibitor for HIV-1, the most com­mon type of HIV.

Lenaca­pavir will be mar­ket­ed in the US as Sun­len­ca for heav­i­ly pre­treat­ed HIV-1 pa­tients who are fail­ing their cur­rent an­ti­retro­vi­ral reg­i­men. The long-act­ing sub­cu­ta­neous in­jec­tion is ad­min­is­tered just twice a year, of­fer­ing an al­ter­na­tive to cum­ber­some dai­ly pill reg­i­mens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER